Purpose: High-dose cisplatin is standard in head and neck cancers. Recently, weekly low-dose platinum alone or with cetuximab has been used. All patients received 70 Gy standard fraction intensity-modulated radiation therapy. We are comparing the former used at the VAMC with the latter regimens used in the department of Oncology at the University of Mississippi. We will present the toxicity, response, patterns of failure, and survival by the use of the different types of chemotherapy.
Conference Coverage
Comparison of Low-Dose Platinum vs High-Dose Platinum vs Cetuximab and Intensity-Modulated Radiation Therapy in Advanced Head and Neck Cancers
Giri S, Kankamedhala M, Suggs JM.
Publish date: September 4, 2014
Abstract 7: 2014 AVAHO Meeting
Clinical Topics
-
When cisplatin won’t do, try carboplatin in head and neck cancer -
Is early-onset cancer an emerging global epidemic? Publish date: October 5, 2022 -
Despite benefits, extended-interval pembro uptake remains low Publish date: September 28, 2022 -
Time to cancer diagnoses in U.S. averages 5 months Publish date: September 15, 2022 -
Trends in Palliative Care Utilization and Facility Type for Stage IV Esophageal Cancer: A National Cancer Database Analysis
Digital Edition
-
Cancer Data Trends 2023 Publish date: July 5, 2023 -
Cancer Data Trends 2022 Publish date: March 30, 2022 -
AVAHO 2021 Meeting Posters and Abstracts Publish date: September 22, 2021 -
Advances in Hematology and Oncology Publish date: September 3, 2021 -
Advances in Hematology and Oncology Publish date: May 20, 2021
Multimedia
-
Palliative Care for Patients With Head and Neck Cancer Publish date: September 14, 2014
Conference Coverage
-
Can some patients with esophageal cancer avoid surgery? Publish date: October 20, 2023 -
Thyroid cancer increase observed in transgender female veterans Publish date: October 6, 2023 -
Triple therapy boosts anaplastic thyroid cancer survival Publish date: October 2, 2023 -
Multiprong strategy makes clinical trials less White Publish date: June 23, 2023 -
CBSM phone app eases anxiety, depression in cancer patients Publish date: June 23, 2023 -
Huge underuse of germline testing for cancer patients Publish date: June 22, 2023 -
ACS officer provides ASCO highlights: Targeting hidden cancer, AI in oncology Publish date: June 15, 2023 -
Metronomic chemotherapy performs well in second-line head and neck cancer Publish date: June 6, 2023 -
Radiofrequency ablation successful in small thyroid cancers Publish date: May 8, 2023 -
A farewell to arms? Drug approvals based on single-arm trials can be flawed Publish date: September 19, 2022
ATA Guidelines: Lymph node dissection & DTC
Question 1 of 5